As Senior VP of Operations at Biojo, Brandon Jurado has over 20 years of diversified experience. He recently spent over eight years in the biopharmaceutical industry as the Director of Strategy & Business Development and Manager of Global Business Development at Mocuis, Co., Ltd., a biopharmaceutical advisory and investment firm. Mr. Jurado collaborated with business, scientific, regulatory, and investor teams in developing strategies for companies of early to middle stage drug assets to advance their therapies to the global markets.

Prior to joining Mocuis, for 15 years Mr. Jurado held positions in healthcare, marketing, and finance. Mr. Jurado holds a Bachelor of Science and an MBA, in addition to, a Master’s in Biotechnology from Johns Hopkins University.

Jenny Jo is the founder and CEO of Biojo Sciences and has a long history of leading companies through multi-national markets. For nine years, Ms. Jo served as the CEO of Mocuis, Co., Ltd, an investment and advisory firm for biopharmaceutical companies which focused on early to middle stage drug assets and companies looking to transition from research to a more focused commercialization strategy. Her roles included establishing strategies across different regulatory territories, global commercialization, partnering, and licensing. During Ms. Jo’s tenure, she was a speaker at the 2015 BIO International Convention on the topic of bringing drugs developed outside of the US, into the US regulatory market. Ms. Jo holds a BA in Business and an MBA, as well as, a Master’s in Biotechnology from Johns Hopkins University.

Dr. Kenneth Carter brings over 25 years of experience in early and clinical-stage biotechnology companies. Dr. Carter has been Chairman of Seneca Biopharma since 2019.  He was CEO & President 2012-2017 at Neximmune, an immuno-oncology company spun out of Johns Hopkins and was involved as a special advisor during their successful $30M fundraise in 2018. Dr. Carter founded Avalon Pharmaceuticals in 1999 and served as CEO for ten years until 2009. During his tenure, Avalon completed an IPO on the NASDAQ and established partnerships with Merck, Novartis, Sanofi-Aventis, and AstraZeneca. Prior to Avalon, Dr. Carter directed the gene mapping initiative at Human Genome Sciences.

Dr. Carter has served on numerous corporate and advisory boards including the National BIO Industry Organization, Antidote Therapeutics, Inc., Iterion Pharmaceuticals and the Maryland BioHealth Initiative (BHI). He is also an adjunct faculty member at John Hopkins University.